Ligand reports planned acquisition of Pfenex
Ligand Pharmaceuticals Inc. (LGND) announced that it has inked a definitive agreement with Pfenex Inc. (PFNX) for acquiring the latter. The companies expect the transaction to be closed in the fourth quarter of 2020, subject to required regulatory approvals. Ligand is expected to provide a detailed outlook for the Pfenex business after the closure of the transaction.
The terms of the agreement states that Ligand will come up with a tender offer to acquire all the outstanding shares of Pfenex Inc. The stock of the